Skip to main content
Epicel

Nexobrid is now approved
for use in the U.S.

Vericel manufactures and markets two advanced cell therapy products for sports medicine and severe burn care in the United States and holds an exclusive license for North American commercial rights to NexoBrid®, a biological orphan product approved for eschar removal of severe thermal burns. Please use the links to the right to visit our product websites.

NASDAQ: VCEL

$28.37 0 (0%)
Day High: $28.71
Day Low: $27.285
Volume: 0
4:00 PM on
February 1, 2023
Copyright West LLC. Minimum 15 minutes delayed.

Company Presentation